Skip to main content

Andrew N. Antoszyk

Assistant Consulting Professor of Ophthalmology
Ophthalmology

Selected Publications


Home OCT Imaging for Newly Diagnosed Neovascular Age-Related Macular Degeneration: A Feasibility Study

Journal Article Ophthalmology Retina · April 1, 2024 Objective: To assess the feasibility of daily Home OCT imaging among patients with neovascular age-related macular degeneration (nAMD). Design: Prospective observational study. Participants: Participants with ≥ 1 eye with previously untreated nAMD and visu ... Full text Cite

Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.

Journal Article Ophthalmology · December 28, 2023 PURPOSE: To evaluate the 2-year efficacy, durability, and safety of dual angiopoietin-2 and vascular endothelial growth factor (VEGF) A pathway inhibition with intravitreal faricimab according to a personalized treat-and-extend (T&E)-based regimen with up ... Full text Link to item Cite

Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.

Journal Article Lancet · October 21, 2023 BACKGROUND: Geographic atrophy is a leading cause of progressive, irreversible vision loss. The objectives of OAKS and DERBY were to assess the efficacy and safety of pegcetacoplan compared with sham treatment in patients with geographic atrophy. METHODS: ... Full text Link to item Cite

Randomized Phase IIb Study of Brimonidine Drug Delivery System Generation 2 for Geographic Atrophy in Age-Related Macular Degeneration.

Journal Article Ophthalmol Retina · July 2023 PURPOSE: To evaluate the safety and efficacy of repeat injections of Brimonidine Drug Delivery System (Brimo DDS) Generation 2 (Gen 2) containing 400-μg brimonidine in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD ... Full text Link to item Cite

A Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular Degeneration.

Journal Article Ophthalmology · June 2023 PURPOSE: Neovascular (wet) age-related macular degeneration (nAMD) is driven by VEGFs A, C, and D, which promote angiogenesis and vascular permeability. Intravitreal injections of anti-VEGF-A drugs are the standard of care, but these do not inhibit VEGF-C ... Full text Link to item Cite

Changes in activity impairment and work productivity after treatment for vitreous hemorrhage due to proliferative diabetic retinopathy: Secondary outcomes from a randomized controlled trial (DRCR Retina Network Protocol AB).

Journal Article PLoS One · 2023 BACKGROUND: Vitreous hemorrhage from proliferative diabetic retinopathy can cause severe vision loss. DRCR Retina Network Protocol AB was a randomized clinical trial comparing intravitreal aflibercept versus vitrectomy with panretinal photocoagulation and ... Full text Link to item Cite

Association of Ultra-Widefield Fluorescein Angiography-Identified Retinal Nonperfusion and the Risk of Diabetic Retinopathy Worsening Over Time.

Journal Article JAMA Ophthalmol · October 1, 2022 IMPORTANCE: Presence of predominantly peripheral diabetic retinopathy (DR) lesions on ultra-widefield fluorescein angiography (UWF-FA) was associated with greater risk of DR worsening or treatment over 4 years. Whether baseline retinal nonperfusion assessm ... Full text Link to item Cite

Association of Predominantly Peripheral Lesions on Ultra-Widefield Imaging and the Risk of Diabetic Retinopathy Worsening Over Time.

Journal Article JAMA Ophthalmol · October 1, 2022 IMPORTANCE: Ultra-widefield (UWF) imaging improves the ability to identify peripheral diabetic retinopathy (DR) lesions compared with standard imaging. Whether detection of predominantly peripheral lesions (PPLs) better predicts rates of disease worsening ... Full text Link to item Cite

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.

Journal Article Lancet · February 19, 2022 BACKGROUND: Faricimab is a bispecific antibody that acts through dual inhibition of both angiopoietin-2 and vascular endothelial growth factor A. We report primary results of two phase 3 trials evaluating intravitreal faricimab with extension up to every 1 ... Full text Link to item Cite

Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.

Journal Article Lancet · February 19, 2022 BACKGROUND: To reduce treatment burden and optimise patient outcomes in diabetic macular oedema, we present 1-year results from two phase 3 trials of faricimab, a novel angiopoietin-2 and vascular endothelial growth factor-A bispecific antibody. METHODS: Y ... Full text Link to item Cite

Effect of Intravitreous Anti-Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical Trial.

Journal Article JAMA Ophthalmol · July 1, 2021 IMPORTANCE: The role of anti-vascular endothelial growth factor injections for the management of nonproliferative diabetic retinopathy (NPDR) without center-involved diabetic macular edema (CI-DME) has not been clearly established. OBJECTIVE: To determine ... Full text Link to item Cite

Visual Acuity, Vitreous Hemorrhage, and Other Ocular Outcomes After Vitrectomy vs Aflibercept for Vitreous Hemorrhage Due to Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.

Journal Article JAMA Ophthalmol · July 1, 2021 IMPORTANCE: Although there were no differences in mean visual acuity (VA) over 24 weeks after vitrectomy with panretinal photocoagulation (PRP) vs aflibercept in a randomized clinical trial among eyes with vitreous hemorrhage due to proliferative diabetic ... Full text Link to item Cite

Effect of Intravitreous Aflibercept vs Vitrectomy With Panretinal Photocoagulation on Visual Acuity in Patients With Vitreous Hemorrhage From Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.

Journal Article JAMA · December 15, 2020 IMPORTANCE: Vitreous hemorrhage from proliferative diabetic retinopathy can cause loss of vision. The best management approach is unknown. OBJECTIVE: To compare initial treatment with intravitreous aflibercept vs vitrectomy with panretinal photocoagulation ... Full text Link to item Cite

Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study).

Journal Article Ophthalmology · September 2020 PURPOSE: Assess follow-up treatment and clinical outcomes at 5 years in eyes initially treated with anti-VEGF therapy for center-involved diabetic macular edema (CI-DME) in a 2-year randomized clinical trial. DESIGN: Multicenter cohort study. PARTICIPANTS: ... Full text Link to item Cite

Phase 1 Study of OPT-302 Inhibition of Vascular Endothelial Growth Factors C and D for Neovascular Age-Related Macular Degeneration.

Journal Article Ophthalmol Retina · March 2020 PURPOSE: OPT-302 is a novel inhibitor of vascular endothelial growth factor (VEGF)-C and VEGF-D. A phase 1 trial assessed the safety of intravitreal OPT-302 as monotherapy or combined with ranibizumab (Lucentis; Genentech, South San Francisco, CA) in patie ... Full text Link to item Cite

Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report Number 19.

Journal Article Ophthalmol Retina · January 2020 PURPOSE: To analyze best-corrected visual acuity (BCVA) outcomes after anti-vascular endothelial growth factor (VEGF) treatment for neovascular age-related macular degeneration (AMD). DESIGN: Prospective cohort study of participants enrolled in a clinical ... Full text Link to item Cite

"Pacman" invasion of the retina: Two cases of ophthalmomyiasis interna posterior.

Journal Article Am J Ophthalmol Case Rep · September 2019 PURPOSE: To discuss two striking cases of ophthalmomyiasis interna posterior, in which the larval stage of a botfly is found in the posterior segment. OBSERVATIONS: In the first case, the subretinal maggot is alive and found to be migrating under the retin ... Full text Link to item Cite

Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial.

Journal Article JAMA · May 21, 2019 IMPORTANCE: Intravitreous injections of antivascular endothelial growth factor agents are effective for treating diabetic macular edema (DME) involving the center of the macula (center-involved DME [CI-DME]) with visual acuity impairment (20/32 or worse). ... Full text Link to item Cite

Natural History of Drusenoid Pigment Epithelial Detachment Associated with Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report No. 17.

Journal Article Ophthalmology · February 2019 PURPOSE: To investigate the natural history and genetic associations of drusenoid pigment epithelial detachment (DPED) associated with age-related macular degeneration (AMD). DESIGN: Retrospective analysis of a prospective cohort study. PARTICIPANTS: Of th ... Full text Link to item Cite

Home OCT Imaging for Newly Diagnosed Neovascular Age-Related Macular Degeneration: A Feasibility Study

Journal Article Ophthalmology Retina · April 1, 2024 Objective: To assess the feasibility of daily Home OCT imaging among patients with neovascular age-related macular degeneration (nAMD). Design: Prospective observational study. Participants: Participants with ≥ 1 eye with previously untreated nAMD and visu ... Full text Cite

Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.

Journal Article Ophthalmology · December 28, 2023 PURPOSE: To evaluate the 2-year efficacy, durability, and safety of dual angiopoietin-2 and vascular endothelial growth factor (VEGF) A pathway inhibition with intravitreal faricimab according to a personalized treat-and-extend (T&E)-based regimen with up ... Full text Link to item Cite

Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.

Journal Article Lancet · October 21, 2023 BACKGROUND: Geographic atrophy is a leading cause of progressive, irreversible vision loss. The objectives of OAKS and DERBY were to assess the efficacy and safety of pegcetacoplan compared with sham treatment in patients with geographic atrophy. METHODS: ... Full text Link to item Cite

Randomized Phase IIb Study of Brimonidine Drug Delivery System Generation 2 for Geographic Atrophy in Age-Related Macular Degeneration.

Journal Article Ophthalmol Retina · July 2023 PURPOSE: To evaluate the safety and efficacy of repeat injections of Brimonidine Drug Delivery System (Brimo DDS) Generation 2 (Gen 2) containing 400-μg brimonidine in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD ... Full text Link to item Cite

A Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular Degeneration.

Journal Article Ophthalmology · June 2023 PURPOSE: Neovascular (wet) age-related macular degeneration (nAMD) is driven by VEGFs A, C, and D, which promote angiogenesis and vascular permeability. Intravitreal injections of anti-VEGF-A drugs are the standard of care, but these do not inhibit VEGF-C ... Full text Link to item Cite

Changes in activity impairment and work productivity after treatment for vitreous hemorrhage due to proliferative diabetic retinopathy: Secondary outcomes from a randomized controlled trial (DRCR Retina Network Protocol AB).

Journal Article PLoS One · 2023 BACKGROUND: Vitreous hemorrhage from proliferative diabetic retinopathy can cause severe vision loss. DRCR Retina Network Protocol AB was a randomized clinical trial comparing intravitreal aflibercept versus vitrectomy with panretinal photocoagulation and ... Full text Link to item Cite

Association of Ultra-Widefield Fluorescein Angiography-Identified Retinal Nonperfusion and the Risk of Diabetic Retinopathy Worsening Over Time.

Journal Article JAMA Ophthalmol · October 1, 2022 IMPORTANCE: Presence of predominantly peripheral diabetic retinopathy (DR) lesions on ultra-widefield fluorescein angiography (UWF-FA) was associated with greater risk of DR worsening or treatment over 4 years. Whether baseline retinal nonperfusion assessm ... Full text Link to item Cite

Association of Predominantly Peripheral Lesions on Ultra-Widefield Imaging and the Risk of Diabetic Retinopathy Worsening Over Time.

Journal Article JAMA Ophthalmol · October 1, 2022 IMPORTANCE: Ultra-widefield (UWF) imaging improves the ability to identify peripheral diabetic retinopathy (DR) lesions compared with standard imaging. Whether detection of predominantly peripheral lesions (PPLs) better predicts rates of disease worsening ... Full text Link to item Cite

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.

Journal Article Lancet · February 19, 2022 BACKGROUND: Faricimab is a bispecific antibody that acts through dual inhibition of both angiopoietin-2 and vascular endothelial growth factor A. We report primary results of two phase 3 trials evaluating intravitreal faricimab with extension up to every 1 ... Full text Link to item Cite

Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.

Journal Article Lancet · February 19, 2022 BACKGROUND: To reduce treatment burden and optimise patient outcomes in diabetic macular oedema, we present 1-year results from two phase 3 trials of faricimab, a novel angiopoietin-2 and vascular endothelial growth factor-A bispecific antibody. METHODS: Y ... Full text Link to item Cite

Effect of Intravitreous Anti-Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical Trial.

Journal Article JAMA Ophthalmol · July 1, 2021 IMPORTANCE: The role of anti-vascular endothelial growth factor injections for the management of nonproliferative diabetic retinopathy (NPDR) without center-involved diabetic macular edema (CI-DME) has not been clearly established. OBJECTIVE: To determine ... Full text Link to item Cite

Visual Acuity, Vitreous Hemorrhage, and Other Ocular Outcomes After Vitrectomy vs Aflibercept for Vitreous Hemorrhage Due to Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.

Journal Article JAMA Ophthalmol · July 1, 2021 IMPORTANCE: Although there were no differences in mean visual acuity (VA) over 24 weeks after vitrectomy with panretinal photocoagulation (PRP) vs aflibercept in a randomized clinical trial among eyes with vitreous hemorrhage due to proliferative diabetic ... Full text Link to item Cite

Effect of Intravitreous Aflibercept vs Vitrectomy With Panretinal Photocoagulation on Visual Acuity in Patients With Vitreous Hemorrhage From Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.

Journal Article JAMA · December 15, 2020 IMPORTANCE: Vitreous hemorrhage from proliferative diabetic retinopathy can cause loss of vision. The best management approach is unknown. OBJECTIVE: To compare initial treatment with intravitreous aflibercept vs vitrectomy with panretinal photocoagulation ... Full text Link to item Cite

Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study).

Journal Article Ophthalmology · September 2020 PURPOSE: Assess follow-up treatment and clinical outcomes at 5 years in eyes initially treated with anti-VEGF therapy for center-involved diabetic macular edema (CI-DME) in a 2-year randomized clinical trial. DESIGN: Multicenter cohort study. PARTICIPANTS: ... Full text Link to item Cite

Phase 1 Study of OPT-302 Inhibition of Vascular Endothelial Growth Factors C and D for Neovascular Age-Related Macular Degeneration.

Journal Article Ophthalmol Retina · March 2020 PURPOSE: OPT-302 is a novel inhibitor of vascular endothelial growth factor (VEGF)-C and VEGF-D. A phase 1 trial assessed the safety of intravitreal OPT-302 as monotherapy or combined with ranibizumab (Lucentis; Genentech, South San Francisco, CA) in patie ... Full text Link to item Cite

Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report Number 19.

Journal Article Ophthalmol Retina · January 2020 PURPOSE: To analyze best-corrected visual acuity (BCVA) outcomes after anti-vascular endothelial growth factor (VEGF) treatment for neovascular age-related macular degeneration (AMD). DESIGN: Prospective cohort study of participants enrolled in a clinical ... Full text Link to item Cite

"Pacman" invasion of the retina: Two cases of ophthalmomyiasis interna posterior.

Journal Article Am J Ophthalmol Case Rep · September 2019 PURPOSE: To discuss two striking cases of ophthalmomyiasis interna posterior, in which the larval stage of a botfly is found in the posterior segment. OBSERVATIONS: In the first case, the subretinal maggot is alive and found to be migrating under the retin ... Full text Link to item Cite

Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial.

Journal Article JAMA · May 21, 2019 IMPORTANCE: Intravitreous injections of antivascular endothelial growth factor agents are effective for treating diabetic macular edema (DME) involving the center of the macula (center-involved DME [CI-DME]) with visual acuity impairment (20/32 or worse). ... Full text Link to item Cite

Natural History of Drusenoid Pigment Epithelial Detachment Associated with Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report No. 17.

Journal Article Ophthalmology · February 2019 PURPOSE: To investigate the natural history and genetic associations of drusenoid pigment epithelial detachment (DPED) associated with age-related macular degeneration (AMD). DESIGN: Retrospective analysis of a prospective cohort study. PARTICIPANTS: Of th ... Full text Link to item Cite

Comparison of Early Treatment Diabetic Retinopathy Study Standard 7-Field Imaging With Ultrawide-Field Imaging for Determining Severity of Diabetic Retinopathy.

Journal Article JAMA Ophthalmol · January 1, 2019 IMPORTANCE: Moderate to substantial agreement between Early Treatment Diabetic Retinopathy Study (ETDRS) 7-field imaging and ultrawide-field (UWF) imaging has been suggested in single-center studies. Comparing images obtained by multiple centers could incr ... Full text Link to item Cite

Progression of Geographic Atrophy in Age-related Macular Degeneration: AREDS2 Report Number 16.

Journal Article Ophthalmology · December 2018 PURPOSE: To analyze the prevalence, incidence, and clinical characteristics of eyes with geographic atrophy (GA) in age-related macular degeneration (AMD), including clinical and genetic factors affecting enlargement. DESIGN: Prospective cohort study withi ... Full text Link to item Cite

Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.

Journal Article JAMA Ophthalmol · October 1, 2018 IMPORTANCE: Ranibizumab is a viable treatment option for eyes with proliferative diabetic retinopathy (PDR) through 2 years. However, longer-term results are needed. OBJECTIVE: To evaluate efficacy and safety of 0.5-mg intravitreous ranibizumab vs panretin ... Full text Link to item Cite

Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema.

Journal Article Ophthalmology · July 2018 PURPOSE: To assess systemic vascular endothelial growth factor (VEGF)-A levels after treatment with intravitreous aflibercept, bevacizumab, or ranibizumab. DESIGN: Comparative-effectiveness trial with participants randomly assigned to 2 mg aflibercept, 1.2 ... Full text Link to item Cite

Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti-Vascular Endothelial Growth Factor Medications: Secondary Outcomes From the SCORE2 Randomized Clinical Trial.

Conference JAMA Ophthalmol · April 1, 2018 IMPORTANCE: Comparisons of monthly vs treat-and-extend anti-vascular endothelial growth factor (anti-VEGF) regimens for macular edema from central retinal vein occlusion or hemiretinal vein occlusion is needed. OBJECTIVE: To compare visual acuity letter sc ... Full text Link to item Cite

EVALUATION OF FULL-FIELD ELECTRORETINOGRAM REDUCTIONS AFTER OCRIPLASMIN TREATMENT: Results of the OASIS Trial ERG Substudy.

Journal Article Retina · February 2018 PURPOSE: To explore a possible association between full-field electroretinograms with vitreomacular adhesion resolution and best-corrected visual acuity as part of the prospective, randomized, double-masked, sham-controlled Ocriplasmin for Treatment for Sy ... Full text Link to item Cite

Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial.

Journal Article JAMA Ophthalmol · January 1, 2018 IMPORTANCE: Some eyes have persistent diabetic macular edema (DME) following anti-vascular endothelial growth factor (anti-VEGF) therapy for DME. Subsequently adding intravitreous corticosteroids to the treatment regimen might result in better outcomes tha ... Full text Link to item Cite

Usability of the Ranibizumab 0.5 mg Prefilled Syringe: Human Factors Studies to Evaluate Critical Task Completion by Healthcare Professionals.

Journal Article PDA J Pharm Sci Technol · 2018 PURPOSE: A ranibizumab prefilled syringe (PFS) has been approved by the U.S. Food and Drug Administration. Here we evaluate the use of the ranibizumab PFS for intravitreal injection by assessing whether the PFS enables healthcare providers to successfully ... Full text Link to item Cite

Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4.

Journal Article JAMA Ophthalmol · June 1, 2017 IMPORTANCE: Macular edema (ME) is the leading cause of decreased visual acuity (VA) associated with retinal vein occlusion (RVO). Identifying factors associated with better outcomes in RVO eyes treated with anti-vascular endothelial growth factor (VEGF) th ... Full text Link to item Cite

Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema.

Journal Article JAMA Ophthalmol · February 2016 IMPORTANCE: Comparisons of the relative effect of 3 anti-vascular endothelial growth factor agents to treat diabetic macular edema warrant further assessment. OBJECTIVE: To provide additional outcomes from a randomized trial evaluating 3 anti-vascular endo ... Full text Link to item Cite

Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.

Journal Article JAMA · November 24, 2015 IMPORTANCE: Panretinal photocoagulation (PRP) is the standard treatment for reducing severe visual loss from proliferative diabetic retinopathy. However, PRP can damage the retina, resulting in peripheral vision loss or worsening diabetic macular edema (DM ... Full text Link to item Cite

Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study.

Journal Article BMC Ophthalmol · October 30, 2015 BACKGROUND: Dexamethasone intravitreal implant 0.7 mg (DEX 0.7) was approved for treatment of diabetic macular edema (DME) after demonstration of its efficacy and safety in the MEAD registration trials. We performed subgroup analysis of MEAD study results ... Full text Link to item Cite

Subretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments Trials.

Journal Article Ophthalmology · September 2015 PURPOSE: To evaluate the association of subretinal hyperreflective material (SHRM) with visual acuity (VA), geographic atrophy (GA), and scar in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). DESIGN: Prospective cohort study w ... Full text Link to item Cite

Assessing the Effect of Personalized Diabetes Risk Assessments During Ophthalmologic Visits on Glycemic Control: A Randomized Clinical Trial.

Journal Article JAMA Ophthalmol · August 2015 IMPORTANCE: Optimization of glycemic control is critical to reduce the number of diabetes mellitus-related complications, but long-term success is challenging. Although vision loss is among the greatest fears of individuals with diabetes, comprehensive per ... Full text Link to item Cite

Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.

Journal Article N Engl J Med · March 26, 2015 BACKGROUND: The relative efficacy and safety of intravitreous aflibercept, bevacizumab, and ranibizumab in the treatment of diabetic macular edema are unknown. METHODS: At 89 clinical sites, we randomly assigned 660 adults (mean age, 61±10 years) with diab ... Full text Link to item Cite

Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3.

Journal Article JAMA Ophthalmol · February 2014 IMPORTANCE: The Age-Related Eye Disease Study (AREDS) formulation for the treatment of age-related macular degeneration (AMD) contains vitamin C, vitamin E, beta carotene, and zinc with copper. The Age-Related Eye Disease Study 2 (AREDS2) assessed the valu ... Full text Link to item Cite

Detachable microsphere scalpel tips for potential use in ophthalmic surgery with the erbium:YAG laser.

Journal Article J Biomed Opt · January 2014 Vitreoretinal surgery is performed using mechanical dissection that sometimes results in iatrogenic complications, including vitreous hemorrhage, retinal breaks, incomplete membrane delamination, retinal distortion, microscopic damage, etc. An ultraprecise ... Full text Link to item Cite

Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4.

Journal Article JAMA Ophthalmol · July 2013 IMPORTANCE: Age-related cataract is a leading cause of visual impairment in the United States. The prevalence of age-related cataract is increasing, with an estimated 30.1 million Americans likely to be affected by 2020. OBJECTIVE: To determine whether dai ... Full text Link to item Cite

Contact focusing multimodal probes for potential use in ophthalmic surgery with the Erbium:YAG laser

Conference Progress in Biomedical Optics and Imaging - Proceedings of SPIE · June 7, 2013 Vitreoretinal surgery is performed using mechanical dissection that sometimes results in iatrogenic complications, including vitreous hemorrhage, retinal breaks, incomplete membrane delamination, retinal distortion, microscopic damage, etc. The laser probe ... Full text Cite

Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial.

Journal Article JAMA · May 15, 2013 IMPORTANCE: Oral supplementation with the Age-Related Eye Disease Study (AREDS) formulation (antioxidant vitamins C and E, beta carotene, and zinc) has been shown to reduce the risk of progression to advanced age-related macular degeneration (AMD). Observa ... Full text Link to item Cite

Novel microsphere chain fiber tips for use in mid-infrared ophthalmic laser surgery

Conference Progress in Biomedical Optics and Imaging - Proceedings of SPIE · June 13, 2012 Ophthalmic surgery may benefit from the use of more precise fiber delivery systems for laser surgery. In this study, chains of sapphire microspheres integrated into the distal tip of a hollow waveguide are used for preliminary midinfrared, Erbium:YAG laser ... Full text Cite

Characterization of novel microsphere chain fiber optic tips for potential use in ophthalmic laser surgery.

Journal Article J Biomed Opt · June 2012 Ophthalmic surgery may benefit from use of more precise fiber delivery systems during laser surgery. Some current ophthalmic surgical techniques rely on tedious mechanical dissection of tissue layers. In this study, chains of sapphire microspheres integrat ... Full text Link to item Cite

HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration.

Journal Article Ophthalmology · June 2012 OBJECTIVE: To evaluate the long-term safety and efficacy of multiple intravitreal ranibizumab injections (Lucentis, Genentech, Inc., South San Francisco, CA) administered at the investigator's discretion in patients with choroidal neovascularization second ... Full text Link to item Cite

Observational study of subclinical diabetic macular edema.

Journal Article Eye (Lond) · June 2012 PURPOSE: To determine the rate of progression of eyes with subclinical diabetic macular edema (DME) to clinically apparent DME or DME necessitating treatment during a 2-year period. METHODS: In all, 43 eyes from 39 study participants with subclinical DME, ... Full text Link to item Cite

Ultra-precise focusing multimodal microprobes for contact laser tissue surgery

Conference Optics InfoBase Conference Papers · December 1, 2011 Using numerical modeling it is demonstrated that chains of spheres with a refractive index of 1.65-1.75 provide two times more compact focused beams compared to single spheres under conditions of illumination typical for laser surgery. © 2011 Optical Socie ... Cite

Ultra-precise focusing multimodal microprobes for contact laser tissue surgery

Conference 2011 Conference on Lasers and Electro-Optics: Laser Science to Photonic Applications, CLEO 2011 · September 1, 2011 Using numerical modeling it is demonstrated that chains of spheres with a refractive index of 1.65-1.75 provide two times more compact focused beams compared to single spheres under conditions of illumination typical for laser surgery. © 2011 OSA. ... Cite

Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation.

Journal Article Retina · June 2011 PURPOSE: To evaluate 14-week effects of intravitreal ranibizumab or triamcinolone in eyes receiving focal/grid laser for diabetic macular edema and panretinal photocoagulation. METHODS: Three hundred and forty-five eyes with a visual acuity of 20/320 or be ... Full text Link to item Cite

Focusing capability of integrated chains of microspheres in the limit of geometrical optics

Conference Proceedings of SPIE - The International Society for Optical Engineering · April 22, 2011 The effects of periodical focusing of light were studied in chains of sapphire microspheres with 300 μm diameters assembled either on a substrate or inside capillary tubing. Dye-doped fluorescent microspheres were used as multimodal sources of light in exp ... Full text Cite

Contact focusing multimodal microprobes for ultraprecise laser tissue surgery.

Journal Article Opt Express · February 14, 2011 Focusing of multimodal beams by chains of dielectric microspheres assembled directly inside the cores of hollow waveguides is studied by using numerical ray tracing. The device designs are optimized for laser surgery in contact mode with strongly absorbing ... Full text Link to item Cite

Integrated microsphere arrays: Light focusing and propagation effects

Conference Proceedings of SPIE - The International Society for Optical Engineering · May 3, 2010 Integration of microspheres inside micro-capillaries or hollow waveguides may allow development of compact focusing tools for a variety of biomedical and photonics applications. However, problems associated with developing focusing microprobes involve the ... Full text Cite

SCORE Study Report 7: incidence of intravitreal silicone oil droplets associated with staked-on vs luer cone syringe design.

Journal Article Am J Ophthalmol · November 2009 PURPOSE: To evaluate the incidence of intravitreal silicone oil (SO) droplets associated with intravitreal injections using a staked-on vs luer cone syringe design in the SCORE (Standard Care vs COrticosteroid in REtinal Vein Occlusion) Study. DESIGN: Pros ... Full text Link to item Cite

SCORE Study report 3: study design and baseline characteristics.

Journal Article Ophthalmology · September 2009 OBJECTIVE: To describe the baseline characteristics of the participants in the Standard Care versus COrticosteroid for REtinal Vein Occlusion (SCORE) Study and to compare with cohorts from other retinal vein occlusion trials. The design of the SCORE Study ... Full text Link to item Cite

Description of the Age-Related Eye Disease Study 9-step severity scale applied to participants in the Complications of Age-related Macular Degeneration Prevention Trial.

Journal Article Arch Ophthalmol · September 2009 OBJECTIVE: To describe characteristics of the Age-Related Eye Disease Study (AREDS) 9-step severity scale applied to participants in the Complications of Age-related Macular Degeneration Prevention Trial (CAPT). METHODS: Eligibility criteria for CAPT requi ... Full text Link to item Cite

Retinal effects of 6 months of daily use of tadalafil or sildenafil.

Journal Article Arch Ophthalmol · April 2009 OBJECTIVE: To assess changes in electroretinography (ERG) and other retinal function parameters during 6 months of daily use of tadalafil, sildenafil citrate, or placebo. METHODS: Subjects were randomized to use of a placebo (n=82), 5 mg of tadalafil (n=85 ... Full text Link to item Cite

Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings.

Journal Article Arch Ophthalmol · February 2009 OBJECTIVE: To compare the effects of single-sitting vs 4-sitting panretinal photocoagulation (PRP) on macular edema in subjects with severe nonproliferative or early proliferative diabetic retinopathy with relatively good visual acuity and no or mild cente ... Full text Link to item Cite

Night vision symptoms and progression of age-related macular degeneration in the Complications of Age-related Macular Degeneration Prevention Trial.

Journal Article Ophthalmology · November 2008 OBJECTIVE: To describe baseline night vision symptoms and their association with >/=3-lines loss in visual acuity (VA), choroidal neovascularization (CNV), and geographic atrophy (GA). DESIGN: Cohort study within a multicenter randomized clinical trial. PA ... Full text Link to item Cite

Retinal thickness on Stratus optical coherence tomography in people with diabetes and minimal or no diabetic retinopathy.

Journal Article Am J Ophthalmol · May 2008 PURPOSE: To evaluate optical coherence tomography (OCT) thickness of the macula in people with diabetes but minimal or no retinopathy and to compare these findings with published normative data in the literature from subjects reported to have no retinal di ... Full text Link to item Cite

Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results.

Journal Article Am J Ophthalmol · May 2008 PURPOSE: To assess the efficacy and adverse-events profile of combined treatment with ranibizumab and verteporfin photodynamic therapy (PDT) in patients with predominantly classic choroidal neovascularization (CNV) secondary to neovascular age-related macu ... Full text Link to item Cite

A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features.

Journal Article Retina · 2008 PURPOSE: To compare baseline demographic, systemic, and ocular characteristics within age and racial subgroups among participants in this Diabetic Retinopathy Clinical Research Network clinical trial and to compare this cohort with other cohorts enrolled i ... Full text Link to item Cite

Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema.

Conference Ophthalmology · March 2007 OBJECTIVE: To compare optical coherence tomography (OCT)-measured retinal thickness and visual acuity in eyes with diabetic macular edema (DME) both before and after macular laser photocoagulation. DESIGN: Cross-sectional and longitudinal study. PARTICIPAN ... Full text Link to item Cite

Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration.

Journal Article Ophthalmology · February 2007 OBJECTIVE: An examination of clinically relevant subgroups of patients in the MARINA study of ranibizumab in treatment of minimally classic or occult with no classic choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) was ... Full text Link to item Cite

Diurnal variation in retinal thickening measurement by optical coherence tomography in center-involved diabetic macular edema.

Journal Article Arch Ophthalmol · December 2006 OBJECTIVE: To evaluate diurnal variation in retinal thickness measured with optical coherence tomography (OCT) in patients with center-involved diabetic macular edema. METHODS: Serial OCT3 measurements were performed in 156 eyes of 96 subjects with clinica ... Full text Link to item Cite

Laser treatment in patients with bilateral large drusen: the complications of age-related macular degeneration prevention trial.

Journal Article Ophthalmology · November 2006 OBJECTIVE: To evaluate the efficacy and safety of low-intensity laser treatment in the prevention of visual acuity (VA) loss among participants with bilateral large drusen. DESIGN: Multicenter randomized clinical trial. One eye of each participant was assi ... Full text Link to item Cite

Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study.

Journal Article Ophthalmology · April 2006 OBJECTIVE: To assess safety of repeated intravitreal injections of ranibizumab in treating neovascular age-related macular degeneration (AMD), and to assess changes in visual acuity (VA) and AMD lesion characteristics. DESIGN: Multicenter, controlled, open ... Full text Link to item Cite

Baseline characteristics, the 25-Item National Eye Institute Visual Functioning Questionnaire, and their associations in the Complications of Age-Related Macular Degeneration Prevention Trial (CAPT).

Journal Article Ophthalmology · July 2004 OBJECTIVE: To describe characteristics of participants in the Complications of Age-Related Macular Degeneration Prevention Trial (CAPT) at baseline and to investigate associations among visual function, fundus features, and vision-related quality of life. ... Full text Link to item Cite

Retinal tear and detachment after transpupillary thermotherapy for choroidal melanoma.

Journal Article Am J Ophthalmol · May 2003 PURPOSE: To report a side effect of transpupillary thermotherapy for choroidal melanoma. DESIGN: Small case series. METHODS: Review of clinical charts and photographs in a private retina practice. RESULTS: Retinal tears developed in two patients after tran ... Full text Link to item Cite

The effect of the surgeon and the laser wavelength on the response to focal photocoagulation for diabetic macular edema.

Journal Article Ophthalmology · February 1999 OBJECTIVE: To determine the effect of the surgeon and the wavelength of laser used on the response to focal photocoagulation for diabetic macular edema. DESIGN: Retrospective case-control study. PARTICIPANTS: Forty-four matched pairs of cases by two differ ... Full text Link to item Cite

Laser chorioretinal venous anastomosis for nonischemic central retinal vein occlusion.

Journal Article Ophthalmology · April 1998 OBJECTIVE: This study aimed to test the efficacy and safety of laser chorioretinal anastomosis for central retinal vein occlusion (CRVO). DESIGN: The study design was a consecutive case series. PARTICIPANTS: Eight eyes of eight patients were treated. INTER ... Full text Link to item Cite

THE SAFETY OF INTRAVITREAL GENISTEIN IN RABBITS, A CLINICAL AND HISTOLOGIC-STUDY

Journal Article INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE · March 15, 1993 Link to item Cite

THE EFFECT OF INTRA-VITREAL LONG ARG IGF-I IN THE RABBIT EYE

Journal Article INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE · March 15, 1993 Link to item Cite

The effects of intravitreal triamcinolone acetonide on experimental pre-retinal neovascularization.

Journal Article Graefes Arch Clin Exp Ophthalmol · 1993 Corticosteroids, alone or in combination with other drugs, have been shown to inhibit angiogenesis. The purpose of this study was to evaluate the efficacy of triamcinolone acetonide in a new model of preretinal neovascularization. Rabbit eyes were treated ... Full text Link to item Cite

Photic maculopathy after extracapsular cataract surgery. A prospective study.

Journal Article Ophthalmology · May 1992 Photic retinal injuries have been described after surgical exposure to the intense illumination systems of operating microscopes. The overall incidence of such injuries has been postulated at less than 10%. The authors prospectively studied 43 consecutive ... Full text Link to item Cite

SUPRESSION OF EXPERIMENTAL PRE-RETINAL NEOVASCULARIZATION WITH INTRAVITREAL TRIAMCINOLONE ACETONIDE

Journal Article INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE · March 15, 1991 Link to item Cite

An experimental model of preretinal neovascularization in the rabbit.

Journal Article Invest Ophthalmol Vis Sci · January 1991 Although progressive retinal neovascularization is a potentially blinding complication of several diseases, there are no good animal models. The authors developed a consistent model of preretinal neovascularization in the rabbit by partially digesting the ... Link to item Cite

The safety of intravitreal hyaluronidase. A clinical and histologic study.

Journal Article Invest Ophthalmol Vis Sci · November 1990 The authors previously developed a new model of preretinal neovascularization in the rabbit eye using hyaluronidase for enzymatic vitreolysis. The purpose of this study was to evaluate the safety of intravitreal injections of hyaluronidase. Concentrations ... Link to item Cite

Silicone oil injection after failed primary vitreous surgery in severe ocular trauma.

Journal Article Am J Ophthalmol · May 15, 1989 In 42 cases of complicated retinal detachment following trauma after failed primary vitrectomy, at six months follow-up anatomic retinal reattachment posterior to the scleral buckle was achieved in 20 of 40 eyes (50%). Of the 40 eyes, 11 (28%) had a visual ... Full text Link to item Cite

Subretinal hemorrhage during fluorescein angiography.

Journal Article Am J Ophthalmol · January 15, 1987 Full text Link to item Cite

Gelatin implants in glaucoma filtering surgery.

Journal Article Am J Ophthalmol · May 15, 1986 Full text Link to item Cite

Contralateral decreased visual acuity and extraocular muscle palsies following retrobulbar anesthesia.

Journal Article Ophthalmology · April 1986 Numerous complications resulting from retrobulbar injections in the injected eye and orbit have been reported. A rare complication of retrobulbar anesthesia is the occurrence of decreased visual acuity and extraocular muscle palsies in the contralateral ey ... Full text Link to item Cite